Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia

BackgroundGlanzmann thrombasthenia (GT) is a rare congenital platelet function disorder associated with severe bleeding diathesis. Thrombotic manifestations remain condition. We report here the first case of recurrent venous thromboembolism (VTE) successfully treated apixaban in patient GT. Our patient’s morbid obesity was an additional challenge.Key Clinical QuestionThe Key Question to determine if direct oral anticoagulants are suitable for patients both and GT.Clinical ApproachIn our patient, episode VTE occurred after use low dose activated recombinant factor VII minor procedure, whereas second unprovoked. Administration rivaroxaban very quickly led appearance symptoms subsequently poor compliance extension deep vein thrombosis. The switched apixaban, good efficacy safety over cumulative 18 months use.ConclusionThe last updated guidelines now recommend management obesity. Regarding GT, there still insufficient data on anticoagulants. Management thrombotic these remains complex condition could be improved by creation specific international registry.